Sunitinib Reduced the Migration of Ectopic Endometrial Cells via p-VEGFR-PI3K-AKT-YBX1-Snail Signaling Pathway

Xiaodan Fan, Yanyan Tong, Yiting Chen, Yichen Chen
Analytical cellular pathology (Amsterdam) · 2022 · vol. 2022 , pp. 1–9 · doi:10.1155/2022/6042518 · PMID:35837295 · PMC9274230 · W4283748505
article OA: gold CC0 ⤵ 1 in-corpus citation
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Sunitinib inhibited ectopic endometrial cell migration through the p-VEGFR-PI3K-AKT-YBX1-Snail pathway in vitro and reduced lesion size and key protein expression in vivo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis (EMs) is one of the most common gynecological diseases, lacking effective treatment. EMs are currently being treated with small molecule targeted therapy, which has resulted in a significant reduction in patient suffering. Our previous studies have shown that sunitinib plays an obvious role in migration. Consequently, the purpose of this study is to explore the molecular mechanism by which sunitinib suppressed the ectopic endometrial migration. The ectopic endometrial cells from patients were divided into two groups: the control group and the sunitinib group. Co-IP and protein spectrum assay were employed to filtrate differential proteins between two groups, and then, our study discovered a signaling pathway, p-VEGFR-PI3K-AKT-YBX1-Snail, in the cell of EMs. To confirm this signaling pathway, VEGF165 was added to the sunitinib group to upregulate the expression of VEGFR. Next, the expression of p-VEGFR, PI3K, AKT, YBX1, and snail was measured in the control group and sunitinib group (compared with the control group: p-VEGFR, PI3K, AKT, YBX1, and snail, ∗∗∗∗P < 0.0001) and the VEGFR+sunitinib group (compared with the sunitinib group: p-VEGFR, PI3K, AKT, and snail, ∗∗∗∗P < 0.0001; YBX1, ∗∗∗P < 0.001); finally, the outcome was as expected. In addition to in vitro experiments, we also conducted in vivo experiments in mice. In the EMs mouse model, we found sunitinib reduced the number of heterotopic foci (t = 11.16, ∗∗∗∗P < 0.0001) and inhibited the expression of p-VEGFR, YBX1, and snail by immunofluorescence. To sum up, sunitinib exactly reduced the migration of ectopic endometrial cells with the involvement of the p-VEGFR-PI3K-AKT-YBX1-Snail signaling pathway in both in vitro and in vivo experiments. This study suggests that sunitinib presents a potential targeted drug for EMs therapy.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Phosphatidylinositol 3-Kinases Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt Proto-Oncogene Proteins c-akt

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (26)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-14T06:08:20.186862+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-15T06:13:33.861732+00:00
License: CC0 · commercial use OK